Structure Therapeutics Inc.
NASDAQ:GPCRBiotechnology
+$0.39 today
- Market cap
- $1.05B
- Beta
- -1.42
- P/E (TTM)
- -19.3
- EPS (TTM)
- -$2.35
Volume 0.58M
Average 0.87M
GPCR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Structure Therapeutics Inc.NASDAQ: GPCR
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$105.93M, compared with -$61.23M a year earlier. Trailing-twelve-month EBITDA was -$212.44M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -12.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$105.93M-41.6% QoQ
- Last fiscal yearDec 2025
- -$136.79M-12.8% YoY
- LTMJun 2026
- -$212.44M-19.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -73.0% | +100.0% | +173.0 pp |
| 1 year | -12.8% | +100.0% | +112.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (136.79M) USD
- Year-over-year change
- -12.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (136.79M) | -12.8% |
| FY2024 | 2024-12-31 | (121.22M) | -60.1% |
| FY2023 | 2023-12-31 | (75.7M) | -48.3% |
| FY2022 | 2022-12-31 | (51.03M) | -35.6% |
| FY2021 | 2021-12-31 | (37.62M) | — |
EBITDA vs competitors
How GPCR compares with its peers on the latest reported figures
- GPCR's LTM Jun 2026 EBITDA of -$212.44M is the 7th highest of the 8 companies compared; the peer median is -$89.21M.
- Its year-over-year change of -19.8% is the 4th highest of 7, against a peer median of -2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$715K | +96.9% | — | 1.9% | |
| LTM Mar 2026 | -$46.12M | +63.6% | — | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$57.07M | +24.4% | — | 59.3% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.21M | -28.4% | — | 864.8% |
| LTM Mar 2026 | -$119.51M | -312.9% | — | 597.6% | |
KLRAKailera Therapeutics, Inc. | FY2025 | -$158.03M | — | — | — |
| LTM Jun 2026 | -$212.44M | -19.8% | — | — | |
| LTM Jun 2026 | -$349.54M | -83.3% | — | — | |
| Peer median (excluding GPCR) | -$89.21M | -2.0% | — | 328.4% | |
Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.9M |
| Gross Profit | 0 | 0 | 0 | 0 | (3.9M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 29.11M | 36.19M | 70.1M | 108.81M | 225.26M |
| Selling, General & Admin | 8.59M | 16.37M | 32.67M | 49.41M | 61.55M |
| Operating Expenses | 37.7M | 52.56M | 102.78M | 158.23M | 283.67M |
| Depreciation & Amortization | 72K | 277K | 295K | 992K | 3.9M |
| EBITDA | (37.62M) | (51.03M) | (75.7M) | (121.22M) | (136.79M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (37.7M) | (52.56M) | (102.78M) | (158.23M) | (287.57M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 122 | 1.26M | 13.38M | 36.03M | 35.97M |
| Interest Expense | 122.16K | 0 | 13.39M | 0 | 0 |
| Other Income / Expenses | (122K) | 1.26M | 13.39M | 36.01M | 146.51M |
| Income Before Tax | (37.82M) | (51.3M) | (89.38M) | (122.22M) | (140.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 231K | 17K | 236K | 310K | 515K |
| Net Income | (40.01M) | (51.32M) | (89.62M) | (122.53M) | (141.2M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.20) | (1.44) | (2.43) | (2.34) | (2.40) |
| EPS (Diluted) | (1.20) | (1.44) | (2.43) | (2.34) | (2.40) |
| Weighted Avg Shares | 36.59M | 36.59M | 36.73M | 52.64M | 59.2M |
| Weighted Avg Shares (Diluted) | 36.59M | 36.59M | 36.73M | 52.64M | 59.2M |
Structure Therapeutics Inc.
NASDAQ:GPCR
Intrinsic Alpha fair value
Locked
Current Price
$18.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.